For two additional recessive variants (rs137853120 in TMPRSS6 for iron-refractory iron deficiency anemia and rs5030764 in GP9 for Bernard-Soulier Syndrome) we observed no homozygous carriers, but heterozygous carriers were around 3 times more likely to have blood indices outside the normal range (hemoglobin < 12 g/dl, PLT < 150×109/l), demonstrating previously unreported dosage-dependent effects (OR = 3.25, 95% CI = 1.85, 5.37, p = 5×10−5 [Figures 6A and 6B] and OR = 3.79, 95% CI = 2.40–5.68, p = 1.1×10−9, respectively). This evidence concerns the gene GP9 and IRIDA syndrome.